

Review

# Adenylyl Cyclase in Ocular Health and Disease: A Comprehensive Review

Polly Thompson <sup>1</sup>, Virginija Vilkelyte <sup>2</sup>, Malgorzata Woronkiewicz <sup>3,4</sup>, Mitra Tavakoli <sup>2</sup>, Piotr Skopinski <sup>5,6</sup> and Harry Roberts <sup>1,2,\*</sup>

<sup>1</sup> West of England Eye Unit, Royal Devon University Healthcare NHS Foundation Trust, Exeter EX2 5DW, UK; polly.thompson5@nhs.net

<sup>2</sup> University of Exeter Medical School, St Luke's Campus, University of Exeter, Exeter EX1 2HZ, UK

<sup>3</sup> NDDH, Royal Devon University Healthcare NHS Foundation Trust, Barnstaple EX31 4JB, UK; malgorzata.woronkiewicz.14@alumni.ucl.ac.uk

<sup>4</sup> Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK

<sup>5</sup> Department of Ophthalmology, SPKSO Ophthalmic University Hospital, Medical University of Warsaw, 00-576 Warsaw, Poland

<sup>6</sup> Department of Histology and Embryology, Medical University of Warsaw, 02-004 Warsaw, Poland

\* Correspondence: harry.roberts@nhs.net

**Simple Summary:** Adenylyl cyclase is an enzyme that plays an important role in cellular signalling in mammals. This review gathers current understanding of the role of adenylyl cyclase in the eye, covering the cornea, lens, retina, lacrimal gland and tear film, and explores their potential as targets for therapeutic innovation.

**Abstract:** Adenylyl cyclases (ACs) are a group of enzymes that convert adenosine-5'-triphosphate (ATP) to cyclic adenosine 3',5' monophosphate (cAMP), a vital and ubiquitous signalling molecule in cellular responses to hormones and neurotransmitters. There are nine transmembrane (tmAC) forms, which have been widely studied; however, the tenth, soluble AC (sAC) is less extensively characterised. The eye is one of the most metabolically active sites in the body, where sAC has been found in abundance, making it a target for novel therapeutics and biomarking. In the cornea, AC plays a role in endothelial cell function, which is vital in maintaining stromal dehydration, and therefore, clarity. In the retina, AC has been implicated in axon cell growth and survival. As these cells are irreversibly damaged in glaucoma and injury, this molecule may provide focus for future therapies. Another potential area for glaucoma management is the source of aqueous humour production, the ciliary body, where AC has also been identified. Furthering the understanding of lacrimal gland function is vital in managing dry eye disease, a common and debilitating condition. sAC has been linked to tear production and could serve as a therapeutic target. Overall, ACs are an exciting area of study in ocular health, offering multiple avenues for future medical therapies and diagnostics. This review paper explores the diverse roles of ACs in the eye and their potential as targets for innovative treatments.

**Keywords:** adenylyl cyclase; soluble adenylyl cyclase; cornea; retina; retinal ganglion cells; lacrimal gland; biomarker; dry eye disease



**Citation:** Thompson, P.; Vilkelyte, V.; Woronkiewicz, M.; Tavakoli, M.; Skopinski, P.; Roberts, H. Adenylyl Cyclase in Ocular Health and Disease: A Comprehensive Review. *Biology* **2024**, *13*, 445. <https://doi.org/10.3390/biology13060445>

Received: 31 May 2024

Revised: 12 June 2024

Accepted: 14 June 2024

Published: 18 June 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Adenylyl cyclases (ACs) are a group of enzymes that catalyse the conversion of adenosine-5'-triphosphate (ATP) to cyclic adenosine 3',5' monophosphate (cAMP) [1], a vital intermediate molecule in many signal transduction pathways, including cellular responses to hormones and neurotransmitters. AC originates from a variety of genes and has a regulatory role in nearly all cells [2].

Many structurally diverse inhibitors of AC have been identified. With regard to tmAC, they are divided into four classes: inhibitors that compete with the ATP at the catalytic site; non-competitive inhibitors which mimic the cAMP-transition state; allosteric non-competitive inhibitors which target the diterpene site; and allosteric non-competitive inhibitors which target currently undefined sites [3].

In humans, there are 10 unique AC genes [1]. One of the genes is soluble adenylyl cyclase (sAC), which is the most evolutionarily conserved, but the most recently identified [4]. The other nine genes encode transmembrane adenylyl cyclases (tmAC), which have been suggested to interact G-protein-coupled receptors (GPCRs) [3–7], proteins that detect molecules outside the cell and trigger an intracellular response.

sAC requires a divalent cation (such as  $\text{Ca}^{2+}$ ) and bicarbonate for activation [8–14]. It is expressed in many different cell types and can be found anywhere in the cell. sAC is not a transmembrane protein, nor is it regulated by G proteins. It, instead, interacts with bicarbonate and triggers local cAMP signalling, commonly found in metabolically active tissue. Many such tissues exist within the eye, implicating sAC as a target of study.

The metabolic needs of the various anatomical structure in the eye are wide-ranging. Bicarbonate-stimulated sAC plays a role in regulating the conventional outflow of aqueous in the ciliary body [4,8,15–22]. AC signalling pathways have been identified in animal models of intrinsic eye muscle kinetics, namely iris sphincter and ciliary body contraction through studies of urocortin 2, a peptide related to corticotropin-releasing factor [23–25].

In genetic studies in mice, it has been shown that sAC is necessary for retinal ganglion cell survival and axon growth [18,26]. It is required for the development of amacrine cells and, to a lesser degree, photoreceptors [27]. Choroidal tissue is an area of significant adenylyl (and guanylyl) cyclase second messenger activity, interacting with hormones and neurotransmitters that impact relaxation [28]. AC activation by forskolin in guineapig sclera has been shown to result in myopic shift accompanied by reduced collagen mRNA levels, implicating AC in the development and treatment of short-sightedness [29].

These commonly found and important molecules show promise as focuses for clinical treatments and preventative medicine. The presence of AC in the ciliary body provides a target for glaucoma and intraocular pressure-modulating treatments. There is also a link to lacrimal gland duct fluid secretion found in the study of cystic fibrosis transmembrane conductance regulator (CFTR) knockout mice [30]. Dopamine receptor activation modulates the circadian timing of AC signalling in mouse retina, as AC is the primary enzyme controlling cAMP in dark adapted photoreceptors [31].

The identification of adenylyl cyclases (ACs) in the eye and their anatomical location in the eye presents an important area of study, promising to enhance our physiological understanding and spur the development of new treatments for ophthalmological and other medical conditions. This review summarizes the current knowledge of ACs, with a particular focus on the less-studied soluble adenylyl cyclase (sAC), and elucidates their roles within the eye.

Adenylyl cyclases (ACs) are a group of enzymes that catalyse the conversion of adenosine-5'-triphosphate (ATP) to cyclic adenosine 3',5' monophosphate (cAMP) [1], a vital intermediate molecule in many signal transduction pathways, including cellular responses to hormones and neurotransmitters. AC has a regulatory role in nearly all cells, catalysing the same reaction but originating from unrelated gene families [2].

In humans, there are 10 unique AC genes [1]. One of the genes is soluble adenylyl cyclase (sAC), which is the most evolutionarily conserved but the most recently identified [3]. The other nine genes encode transmembrane adenylyl cyclases (tmAC), which interact physically with G-protein-coupled receptors (GPCRs) [4–6], proteins that detect molecules outside the cell and trigger an intracellular response.

sAC requires a divalent cation (such as  $\text{Ca}^{2+}$ ) and bicarbonate for activation [7–13]. It is expressed in many different cell types and can be found anywhere in the cell [4,7,14–20]. sAC is not a transmembrane protein, nor is it regulated by G proteins. It, instead, interacts


with bicarbonate and triggers local cAMP signalling, commonly found in metabolically active tissue. Many such tissues exist within the eye, implicating sAC as a target of study.

The metabolic needs of the complex anatomical structure in the eye are wide-ranging. Bicarbonate-stimulated sAC plays a role in regulating the conventional outflow of aqueous in the ciliary body [21]. AC signalling pathways have been identified in the animal models of intrinsic eye muscle kinetics, namely iris sphincter and ciliary body contraction through studies of urocortin 2, a peptide related to corticotropin-releasing factor [22–24].

In genetic studies in mice, it has been shown that sAC is necessary for retinal ganglion cell survival and axon growth [16,25]. It is required for the development of amacrine cells and, to a lesser degree, photoreceptors [26]. Choroidal tissue is an area of significant adenylyl (and guanylyl) cyclase second messenger activity, interacting with hormones and neurotransmitters that impact relaxation [27]. AC activation by forskolin in guinea pig sclera has been shown to result in myopic shift accompanied by reduced collagen mRNA levels, implicating AC in the development and treatment of short-sightedness [28].

These commonly found and important molecules show promise as focuses for clinical treatments and preventative medicine. The presence of AC in the ciliary body provides a target for glaucoma and intraocular pressure-modulating treatments. AC-associated proteins have been identified as potential biomarkers for Alzheimer’s disease in the proteomic analysis of tear fluid [29]. There is also a link to lacrimal gland duct fluid secretion found in the study of cystic fibrosis transmembrane conductance regulator (CFTR) knockout mice [30]. Dopamine receptor activation modulates the circadian timing of AC signalling in mouse retina, as AC is the primary enzyme controlling cAMP in dark adapted photoreceptors [31].

The identification of adenylyl cyclases (ACs) in the eye and their anatomical location in the eye present an important area of study, promising to enhance our physiological understanding and spur the development of new treatments for ophthalmological and other medical conditions. This review summarizes the current knowledge of ACs, with a particular focus on the less-studied soluble adenylyl cyclase (sAC), and elucidates their roles within the eye (Figure 1).



**Figure 1.** An overview of some of the functions of adenylyl cyclase (AC) and soluble adenylyl cyclase (sAC) in the eye. (A) The crystalline lens’s response to hypoosmotic stress involves the activation of transient receptor potential cation channel subfamily 4 (TRPV4), which maintains clarity through

cAMP-mediated water and ion channel function. (B) Vasoactive peptide (VIP) released by parasympathetic nerves increases intracellular calcium. This causes smooth muscle cell relaxation and increased AC activity, which results in increased tear secretion. (C) Increased intracellular levels of cAMP catalysed by AC protects retinal ganglion cells (RGCs) from degeneration and promotes neuroprotective astrocyte formation. (D) cAMP is understood to facilitate the drainage of aqueous humour by the conventional outflow pathway, which is formed by the trabecular meshwork (TM) and Schlemm's canal. (E) Increases in cAMP activity (modulated in places by the cystic fibrosis transmembrane conductance regulator (CFTR)) results in increased net endothelial fluid transport.

## 2. Methodology

Our research was conducted using a combination of online databases, including PubMed, Google Scholar, and Web of Science. Keywords such as “adenylyl cyclase”, “AC”, “eye”, “ophthalmology”, and “ocular biomarkers” were employed to identify relevant articles. The search was conducted within a timeline spanning the past two decades to ensure the inclusion of recent developments. Additionally, manual searches of reference lists from relevant articles were performed to identify additional sources. This comprehensive search strategy aimed to gather a diverse range of studies and insights into the role of adenylyl cyclase in the eye.


### 2.1. Soluble Adenylyl Cyclase

In 1975, a different type of adenylyl cyclase was found in mammals, distinct from the trans-membrane types which had been extensively studied [6]. A soluble source of AC activity was detected in the testis, with activity thought to be dependent on manganese and insensitive to G-protein and forskolin regulation. The physiological function, biochemical regulation and molecular nature did not become clear until the sAC protein was purified and cloned in 1999 [3]. sAC has since been identified abundantly in the cornea, ciliary body, retina and in epithelial cells lining the anterior surface of the lens [18,19,32–34].

The single functional sAC gene in the human genome (ADCY10) is composed of 33 exons and spans more than 100 kb, though it uses multiple promoters, with extensive alternative splicing [13]. Full-length mammalian sAC (sAC<sub>fl</sub>) comprises two heterologous catalytic domains (C1 and C2) which make up the 50 kDa amino terminus [13]. When compared to the minimal functional sAC variant (sAC<sub>t</sub>), the extra 140 kDa terminus of sAC<sub>fl</sub> reflects several regulatory functions, such as a canonical P-loop, leucine zipper and autoinhibitory regions. sAC<sub>t</sub>, on the other hand, is almost exclusively comprised of C1 and C2, making it several times stronger at forming cAMP [13].

The key amino acid residues implicated in the catalytic conversion of ATP to cAMP are conserved in cyanobacterial and mammalian sAC. ATP, with Ca<sup>2+</sup> bound to its  $\gamma$ -phosphate, interacts with specific residues in the sAC catalytic centre, resulting in an ‘open sAC state’. Then, the second divalent metal ion binds the  $\alpha$ -phosphate of ATP, leading to a ‘closed state’ [35]. The change from ‘open’ to ‘closed’ induces the esterification of the  $\alpha$ -phosphate with the ribose in adenosine and the simultaneous release of the  $\beta$ - and  $\gamma$ - phosphates (‘cyclising’) [13].

The source of bicarbonate-regulating sAC can be metabolically generated or external to the cell (Figure 2). Carbonic anhydrases (CAs) found both intra- and extra-cellularly are essential for the fast hydration of CO<sub>2</sub> into bicarbonate, which activates sAC [36].



**Figure 2.** The activation of soluble adenylyl cyclase (sAC) by bicarbonate and Ca<sup>2+</sup>. **(A)** Ca<sup>2+</sup> entering the cell through membrane transporters, or potentially from the release of the endoplasmic reticulum or mitochondria. **(B)** Bicarbonate entering through membrane-transporting proteins such as Cystic Fibrosis Transmembrane Conductance Regulators (CFTRs). **(C)** sAC activation in the cytoplasm. **(D)** Bicarbonate- and Ca<sup>2+</sup>-activating sAC in the nucleus. **(E)** sAC activated by metabolically generated CO<sub>2</sub> through carbonic anhydrase (CA). Adapted from Tresguerres et al. [13].

## 2.2. The Cornea

The cornea is a clear, avascular structure through which light enters the eye. Lining the inner surface of the stroma is the corneal endothelium. sAC was first identified in the endothelial layer of cornea by Sun et al. in 2003 [32].

The corneal endothelium allows nutrients from the aqueous humour into the stroma, while also transporting H<sub>2</sub>O out to maintain dehydration of the stroma [37]. This process is stimulated by bicarbonate and follows a Cl<sup>-</sup> gradient [37]. An increase in cAMP activity results in higher net endothelial fluid transport [38]. Li et al. investigated the role of sAC in apoptosis in corneal endothelial cells (CECs) and found that bicarbonate-dependent endogenous sAC activity can initiate antiapoptotic signal transduction, suggesting a role for sAC in cellular protection [39].

The corneal endothelium does not undergo mitosis *in vivo*; therefore, it relies on a large functional reserve of cells. CEC density decreases by approximately 0.5% per year in healthy individuals; however, in those with endothelial dystrophies or following surgery or trauma, the loss of CEC can be devastating for maintaining dehydration of the stroma, leading to reduction in vision [39]. As it is suggested that AC modulation may protect CEC against stress [40], this could be an area of therapeutic interest.

The cAMP-dependent activation of the cystic fibrosis transmembrane conductance regulator (CFTR) regulates fluid transport in many tissues, including CEC, through chloride and bicarbonate ion transport [32]. These processes are essential for maintaining fluid balance and cellular homeostasis. In the corneal endothelium, proper fluid transport is crucial for maintaining corneal transparency and hydration. In cystic fibrosis (CF), defective CFTR leads to altered ion transport and fluid balance in corneal endothelial cells (CECs). This can affect the regulation of intraocular pressure and the corneal dehydration process. It has been demonstrated that bicarbonate-stimulated sAC contributes to baseline cAMP in bovine corneal endothelial cells, therefore affecting CFTR activity [21]. In most cases, patients with CF do not have visual problems. It has, however, been shown that in CF, there

is a significantly higher density of CECs compared to normal, which may be the evidence of compensation for the CFTR defect [41].

### 2.3. The Crystalline Lens

Ion and water balance are essential for preserving lens transparency. Disruptions in this balance can lead to cataracts, characterized by lens opacity and impaired vision [42]. Understanding the role of ACs and calcium signalling in the lens can provide insights into the mechanisms that maintain lens clarity and function, potentially leading to new treatments for cataract prevention and other lens-related disorders.

The lens epithelium is pivotal in regulating the homeostatic functions of the lens, marking it as a region of high metabolic activity associated with adenylyl cyclases (ACs) [43–45]. As in the cornea, proper ion and water homeostasis is required to maintain lens transparency and normal vision.

The lens's response to hypoosmotic stress involves the activation of transient receptor potential cation channel subfamily 4 (TRPV4). This channel facilitates the entry of calcium into the cytoplasm, subsequently activating the calcium-sensitive isoforms of ACs. This mechanism was first demonstrated in porcine lenses by Shahidullah et al. in 2017 [46].

### 2.4. The Ciliary Body

The ciliary body is anatomically situated between the scleral spur and retina. It not only mediates the optical accommodation of the crystalline lens, but also produces aqueous humour (AH) via ultrafiltration [47]. Relaxation of the ciliary muscle in cats has been found to be mediated by both cAMP-dependent and independent mechanisms [48].

AH is produced by pigmented epithelial cells and non-pigmented epithelial cells found in the ciliary processes. This fluid provides nutrients to the avascular tissues in the cornea and lens. AH is continually produced and drained from the eye, exhibiting circadian rhythm which has been found to be governed by AC in rabbit ciliary processes [49]. This process generates intraocular pressure (IOP) through the resistance to drainage of AH.

IOP is essential for maintaining the optical properties and shape of the eye [50]. A rise in IOP causes the death of RGCs; therefore, the treatment of glaucoma aims to lower IOP. Thus, this pathway has been of great interest for developing new ways of preventing vision loss in such a prevalent disease.

cAMP and bicarbonate have established roles in regulating IOP [51–53]. cAMP is understood to facilitate drainage by the conventional outflow pathway, which is formed by the trabecular meshwork (TM) and Schlemm's canal [54–60]. Flow through the TM is governed by many molecules, including prostaglandins (analogues of which are a commonly used therapy in treating glaucoma), which then stimulates AC activity in a dose-dependent fashion [61,62]. A comprehensive review paper on the role of cAMP in glaucoma was produced by Shim et al. in 2017, highlighting RGC regeneration by sAC, as well as optic nerve head astrocyte restoration by tmAC [63].

Bicarbonate sensitive AC was identified in the rabbit ciliary body in 1993 by Mittag et al., and work began to identify molecules that could influence this activity, such as beta-adrenergic agonists [14]. In 2014, Lee et al. described how sAC plays a significant role in the regulation of outflow resistance through their work on mice, noting increases in IOP when an sAC was inhibited [47]. Further characterisation of this pathway, and therefore the regulation of outflow, could potentially provide an area of novel glaucoma therapy.

Acetazolamide is a carbonic anhydrase inhibitor; therefore, it reduces levels of bicarbonate. It is commonly used in treating high IOP. Shahidullah et al. demonstrated how the exposure of acetazolamide to porcine non-pigmented ciliary epithelium increased cAMP in a response that involved the activation of sAC [64]. However, in 2023, Wiggins et al. examined the effect on IOP from brinzolamide (a clinically used carbonic anhydrase inhibitor) and found that sAC knockout, wild-type and wild-type mice treated with sAC inhibitors all showed a significant decrease in IOP, thereby suggesting that the signalling cascade by which brinzolamide regulates IOP does not involve sAC in mice [65]. Further re-

search to elucidate the exact pharmacodynamics could lead to better medicine management and patient-targeted therapies. A review paper by Agarwal et al. in 2014 discusses new targets of the modulation of IOP, with a focus on adenosine receptor signalling pathways, including the activation of AC [66].

### 2.5. The Retina

The retina is composed of photoreceptive cells and layers of neurons and glia. cAMP and AC are understood to play a role in many aspects of vision, including neuritic sprouting [67,68], dopamine (DA) release [69] and the generation of the retinal response to light [70]. Most research on sAC and AC in the retina has focussed on its function in retinal ganglion cells (RGCs) [18,27,71,72] and photoreceptors [73].

RGCs are the neurons that transmit visual information from photoreceptors via bipolar and retina amacrine cells to the brain, with their axons comprising the optic nerve. Most RGCs synapse in the lateral geniculate nucleus. The remaining RGCs involved in pupillary reflexes and circadian functions terminate in other areas of the brain [74]. Their death causes the irreversible vision loss in glaucoma.

In 2009, Dunn et al. first reported a potential role of sAC in  $Ca^{2+}$ -dependent protein kinase A (PKA) signalling [27]. It was found that the signalling pathway still functioned despite the blockade of tmAC, suggesting sAC was responsible for PKA activation. Building on the work of Varella et al., who identified the role of PKA in apoptosis in new-born rat retina [75], other molecules such as the pituitary adenylate cyclase-activating polypeptide (PACAP) have been shown to provide neuroprotection through anti-apoptotic effects [76–78].

In the developing retina, increased intracellular levels of cAMP protect cells from degeneration [79,80]. Corredor et al. studied whether sAC-generated increases in cAMP had an effect on axon growth in RGCs. Bicarbonate was applied to cultured RGCs, where it was found to increase growth but have no impact on cell survival, unlike electrical stimulation. In contrast, electrical stimulation did have an effect on survival [18]. Notably, tmAC inhibitors had no effect on axon survival or growth in mice, which was in line with work by Dunn et al. who suggested tmACs may be less significant than sAC in this respect [27]. The importance of this research lies in its contribution to understanding the signal transduction pathways that govern neuron survival and the potential role they could play in developing therapies for neurodegenerative diseases and central nervous system injuries.

A recent paper by Cameron et al. described the impact sAC and cAMP have on the formation of neuroprotective astrocytes, which subsequently inhibit neurotoxic astrocytes to promote RGC survival [81] and suggest that sAC may be vital in the treatment of glaucoma and other optic neuropathies. Their work also developed a new viral vector to target optic nerve astrocytes, representing an important step in progressing gliotherapeutic approaches.

The reduced form of vitamin C, ascorbate, is highly concentrated in the central nervous system (CNS), including the retina. DA, through  $D_1$ - and  $D_2$ -like receptor subfamilies, are classically coupled to AC. These interactions are known to modulate synaptic transmission in the retina. A study by de Encarnação et al. using primary retinal cultures showed that DA plays a crucial role in regulating ascorbate homeostasis through a signalling pathway involving  $D_1R/AC/cAMP$ / exchange protein directly activated by cAMP type 2 (EPAC2), suggesting that vitamin C may modify DA neurotransmission in the retina [82].

### 2.6. Retinal Disease

Retinopathy of prematurity (ROP) is an ocular disease that can occur in premature babies, before retinal vessels complete their normal growth [83]. The upregulation of the vascular endothelial growth factor (VEGF) through high oxygen at birth, fluctuations in oxygenation, nutrition and poor postnatal growth causes aberrant vessel formation, which can ultimately lead to retinal detachment. An observational case–control-targeted genetic analysis by Paradis et al. found adenylyl cyclase 4 (ADCY4), ADCY7 and ADCY

9 genes (and others) were associated with ROP [83]. The multicentre validation of these newly discovered risk factors could help develop tools for predicting and preventing the development of severe ROP.

Stargardt disease is a severe juvenile form of macular degeneration [84]. It is associated with more than 800 mutations in the ABCA4 gene, an ATP-binding cassette transporter that moves all-trans-retinal from the internal membranes of retinal outer segment discs to the cytoplasm, where it is reduced by retinol dehydrogenases to retinol. Detailed analysis of AC in the context of Stargardt disease by Chen et al. in 2013 found that pharmacological interventions targeted at both G-protein-coupled receptor signalling pathways and AC improved photoreceptor cell survival, attenuated the pathological deposits in the retina and persevered photoreceptor function [84].

### 2.7. Retinal Circadian Rhythm

Photoreceptor metabolic activity varies significantly in dark versus light, causing changes in CO<sub>2</sub>/bicarbonate concentration in the outer retina [85]. A study on cell lines derived from human retinal pigment epithelium by Pavan et al. in 2006 demonstrated a circadian rhythm in the expression of AC and clock genes, which could then represent relevant drug targets for diseases involving circadian dysfunctions [31].

Research on chicken embryo retina found that the activation of AMP-activated protein kinase A (AMPK), downstream of AC, is under circadian control, and anti-phase to the retinal ATP rhythm [86–88]. Further research by Hwang et al. investigated the circadian rhythm of contrast sensitivity in RGCs [89]. Spatial variation in light intensity (known as spatial contrast) makes up the majority of the visual information perceived by mammals. Contrast sensitivity is the relative ability to detect contrast [90]. Retinal dopamine receptors (D4Rs) have been implicated in this process, functioning alongside a clock-controlled AC gene ADCY1. Contrast sensitivity was found to be reduced in mice lacking ADCY1 [89,91].

Melatonin is synthesized by photoreceptors at high levels at night and lower levels during the day. It exercises its influence by interacting with a family of G-protein-coupled receptors that are negatively coupled with AC. Fukuhara et al. reported that circadian control of the cAMP-signalling cascade was linked to the rhythmic control of type 1 adenylyl cyclase (AC1) expression [92]. Research in the field of exogenous melatonin as a benefit to ocular health is not extensive, but it has certainly been linked to retinal physiology and pathophysiology [93].

Disruption to the circadian rhythm can have grave effects on the physiological functioning of the body. The research into the role of AC within this area may, therefore, have implications for a huge number of homeostatic pathways and their dysfunction.

### 2.8. The Lacrimal Gland

Dry eye is the most common ocular surface disease. In large epidemiological studies, the age-specific prevalence ranges from 5 to 30% [94]. Currently, there are only limited treatment options, resulting in significant management challenges. Tear secretion is an intricate process which involves main and accessory lacrimal glands (LGs), oil-producing Meibomian glands and corneal and conjunctival epithelial goblet cells, which yield mucus. LG dysfunction results in aqueous deficient dry eye.

Vasoactive intestinal peptide (VIP), released by parasympathetic nerves, is an important regulator of lacrimal gland function [95]. It is also a smooth muscle relaxant and vasodilator peptide in the lung [96]. VIP was implicated in the regulation of tear production in the case of a patient with a VIP-secreting metastatic pancreatic adenocarcinoma, who had serum levels 80 times higher than normal and significant tear overproduction [97].

The effect of VIP on ductal fluid secretion was studied by Berczeli et al. in CFTR-knockout mice and wildtypes, with ductal fluid secretion measured with videomicroscopy [30]. In this study, VIP stimulation resulted in a continuous fluid secretion from wildtype mice, as opposed to weak pulse-like secretions from the CFTR-knockout mice. A small (but statistically significant) increase was detected in the intracellular Ca<sup>2+</sup> level, which



implicated the role of the AC-cAMP-CFTR route in this function [30]. LG secretion is mediated by a wide range of ion transporters and channels. This study suggests that the modification of CFTR function may be a target to stimulate LG secretion, and therefore, a possible option in treating aqueous deficient dry eye.

### 3. Conclusions

The exploration of adenylyl cyclases (ACs) across various eye structures offers invaluable insights into their multifaceted roles and potential therapeutic avenues. Pioneering efforts, such as Corredor et al.'s utilization of viral vectors to target sAC in optic nerve astrocytes, signify a pivotal advancement toward practical therapeutic applications [18].

Vision-threatening conditions like corneal trauma, endothelial disease, and glaucoma pose significant challenges. Targeting sAC offers promising avenues for novel treatments by regulating corneal stromal hydration, enhancing corneal endothelial cell survival, and modulating aqueous humour outflow from the ciliary body. Furthermore, the intersection of research on brain injuries, glial survival, and glaucoma underscores the immense value of knowledge sharing across diverse medical domains.

The intricate interplay between sAC, cyclic adenosine monophosphate (cAMP), and the cystic fibrosis transmembrane conductance regulator (CFTR) highlights the potential for broader applications beyond their initial contexts. Notably, the circadian rhythm of AC expression and activity suggests their involvement in regulating ocular circadian functions, presenting novel targets for circadian rhythm disorders.

There are some limitations in the studies covered in this systematic review. ACs are widely found within cell-signalling cascades, which means precise targeting may be a challenge for future therapies. Furthermore, some of the research has been carried out on animal models, which makes assumptions in their relevance to human physiology.

In conclusion, the multifaceted roles of ACs in ocular physiology and pathology position them as promising targets for continued research and the development of innovative therapeutic interventions in ophthalmology and related disciplines, paving the way for enhanced patient care and improved visual outcomes.

**Author Contributions:** All authors have made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Data Availability Statement:** No new data were created or analysed in this study. Data sharing is not applicable to this article.

**Conflicts of Interest:** The authors declare no conflicts of interest.

### Abbreviations

AC	Adenylyl cyclase
AH	Aqueous humour
AMPK	Adenosine monophosphate activated protein kinase A
ATP	Adenosine-5'-triphosphate
CA	Carbonic anhydrase
cAMP	Cyclic adenosine 3',5' monophosphate
CAP1	Adenylyl-cyclase-associated protein 1
CEC	Corneal endothelial cell
CFTR	Cystic fibrosis transmembrane conductance regulator
CNS	Central nervous system
D4R	Retinal dopamine receptor
DA	Dopamine
GPCRs	G-protein coupled receptors
IOP	Intraocular pressure

LG	Lacrimal gland
MS	Multiple sclerosis
PACAP	Pituitary adenylate cyclase-activating polypeptide
PKA	Protein kinase A
RGCs	Retinal ganglion cell
ROP	Retinopathy of prematurity
sAC	Soluble adenylyl cyclase
sAC <sub>fl</sub>	Full-length mammalian Soluble adenylyl cyclase
TM	Trabecular meshwork
TRPV4	Transient receptor potential cation channel subfamily 4
tmAC	Transmembrane adenylyl cyclase
VEGF	Vascular endothelial growth factor
VIP	Vasoactive intestinal peptide

## References

- Smit, M.J.; Iyengar, R. Mammalian adenylyl cyclases. *Adv. Second Messenger Phosphoprot. Res.* **1998**, *32*, 1–21. [[CrossRef](#)] [[PubMed](#)]
- Haber, N.; Stengel, D.; Defer, N.; Roeckel, N.; Mattei, M.G.; Hanoune, J. Chromosomal mapping of human adenylyl cyclase genes type III, type V and type VI. *Hum. Genet.* **1994**, *94*, 69–73. [[CrossRef](#)]
- Seifert, R.; Lushington, G.H.; Mou, T.C.; Gille, A.; Sprang, S.R. Inhibitors of Membranous Adenylyl Cyclases. *Trends Pharmacol. Sci.* **2012**, *33*, 64–78. [[CrossRef](#)] [[PubMed](#)]
- Buck, J.; Sinclair, M.L.; Schapal, L.; Cann, M.J.; Levin, L.R. Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 79–84. [[CrossRef](#)] [[PubMed](#)]
- Defer, N.; Best-Belpomme, M.; Hanoune, J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. *Am. J. Physiol. Ren. Physiol.* **2000**, *279*, F400–F416. [[CrossRef](#)]
- Tang, W.J.; Gilman, A.G. Adenylyl cyclases. *Cell* **1992**, *70*, 869–872. [[CrossRef](#)] [[PubMed](#)]
- Cooper, D.M.F. Regulation and organization of adenylyl cyclases and cAMP. *Biochem. J.* **2003**, *375 Pt 3*, 517–529. [[CrossRef](#)] [[PubMed](#)]
- Garbers, D.L.; Tubb, D.J.; Hyne, R.V. A requirement of bicarbonate for Ca<sup>2+</sup>-induced elevations of cyclic AMP in guinea pig spermatozoa. *J. Biol. Chem.* **1982**, *257*, 8980–8984. [[CrossRef](#)] [[PubMed](#)]
- Okamura, N.; Tajima, Y.; Soejima, A.; Masuda, H.; Sugita, Y. Sodium bicarbonate in seminal plasma stimulates the motility of mammalian spermatozoa through direct activation of adenylate cyclase. *J. Biol. Chem.* **1985**, *260*, 9699–9705. [[CrossRef](#)]
- Garty, N.B.; Salomon, Y. Stimulation of partially purified adenylate cyclase from bull sperm by bicarbonate. *FEBS Lett.* **1987**, *218*, 148–152. [[CrossRef](#)]
- Visconti, P.E.; Muschietti, J.P.; Flawia, M.M.; Tezon, J.G. Bicarbonate dependence of cAMP accumulation induced by phorbol esters in hamster spermatozoa. *Biochim. Biophys. Acta* **1990**, *1054*, 231–236. [[CrossRef](#)]
- Chen, Y.; Cann, M.J.; Litvin, T.N.; Iourgenko, V.; Sinclair, M.L.; Levin, L.R.; Buck, J. Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. *Science* **2000**, *289*, 625–628. [[CrossRef](#)] [[PubMed](#)]
- Tresguerres, M.; Levin, L.R.; Buck, J. Intracellular cAMP signaling by soluble adenylyl cyclase. *Kidney Int.* **2011**, *79*, 1277–1288. [[CrossRef](#)]
- Mittag, T.W.; Guo, W.B.; Kobayashi, K. Bicarbonate-activated adenylyl cyclase in fluid-transporting tissues. *Am. J. Physiol.* **1993**, *264 Pt 2*, F1060–F1064. [[CrossRef](#)]
- Schmid, A.; Sutto, Z.; Nlend, M.-C.; Horvath, G.; Schmid, N.; Buck, J.; Levin, L.R.; Conner, G.E.; Fregien, N.; Salathe, M. Soluble adenylyl cyclase is localized to cilia and contributes to ciliary beat frequency regulation via production of cAMP. *J. Gen. Physiol.* **2007**, *130*, 99–109. [[CrossRef](#)] [[PubMed](#)]
- Braun, T.; Dods, R.F. Development of a Mn<sup>2+</sup>-sensitive, “soluble” adenylate cyclase in rat testis. *Proc. Natl. Acad. Sci. USA* **1975**, *72*, 1097–1101. [[CrossRef](#)]
- Chen, J.; Levin, L.R.; Buck, J. Role of soluble adenylyl cyclase in the heart. *Am. J. Physiol.-Heart Circ. Physiol.* **2012**, *302*, H538–H543. [[CrossRef](#)]
- Corredor, R.G.; Trakhtenberg, E.F.; Pita-Thomas, W.; Jin, X.; Hu, Y.; Goldberg, J.L. Soluble adenylyl cyclase activity is necessary for retinal ganglion cell survival and axon growth. *J. Neurosci. Off. J. Soc. Neurosci.* **2012**, *32*, 7734–7744. [[CrossRef](#)] [[PubMed](#)]
- Lee, Y.S.; Tresguerres, M.; Hess, K.; Marmorstein, L.Y.; Levin, L.R.; Buck, J.; Marmorstein, A.D. Regulation of anterior chamber drainage by bicarbonate-sensitive soluble adenylyl cyclase in the ciliary body. *J. Biol. Chem.* **2011**, *286*, 41353–41358. [[CrossRef](#)]
- Wertheimer, E.; Krapf, D.; de la Vega-Beltran, J.L.; Sánchez-Cárdenas, C.; Navarrete, F.; Haddad, D.; Escoffier, J.; Salicioni, A.M.; Levin, L.R.; Buck, J.; et al. Compartmentalization of distinct cAMP signaling pathways in mammalian sperm. *J. Biol. Chem.* **2013**, *288*, 35307–35320. [[CrossRef](#)]
- Sun, X.C.; Cui, M.; Bonanno, J.A. [HCO<sub>3</sub><sup>-</sup>]-regulated expression and activity of soluble adenylyl cyclase in corneal endothelial and Calu-3 cells. *BMC Physiol.* **2004**, *4*, 8. [[CrossRef](#)]
- Roa, J.N.; Tresguerres, M. Bicarbonate-sensing soluble adenylyl cyclase is present in the cell cytoplasm and nucleus of multiple shark tissues. *Physiol. Rep.* **2017**, *5*, e13090. [[CrossRef](#)] [[PubMed](#)]

23. Tavares-Silva, M.; Ferreira, D.; Cardoso, S.; Raimundo, A.R.; Barbosa-Breda, J.; Leite-Moreira, A.; Rocha-Sousa, A. Modulation of iris sphincter and ciliary muscles by urocortin 2. *Physiol. Res.* **2018**, *67*, 465–474. [[CrossRef](#)] [[PubMed](#)]
24. Yousufzai, S.Y.; Ye, Z.; Abdel-Latif, A.A. Prostaglandins mediate the stimulatory effects of endothelin-1 on cAMP accumulation and inositol-1,4,5-trisphosphate production and contraction in cat iris sphincter. *J. Pharmacol. Exp. Ther.* **1995**, *275*, 1280–1287. [[PubMed](#)]
25. Abdel-Latif, A.A.; Yousufzai, S.Y.; De, S.; Tachado, S.D. Carbachol stimulates adenylate cyclase and phospholipase C and muscle contraction-relaxation in a reciprocal manner in dog iris sphincter smooth muscle. *Eur. J. Pharmacol.* **1992**, *226*, 351–361. [[CrossRef](#)] [[PubMed](#)]
26. Mittag, T.W.; Tormay, A.; Severin, C.; Taniguchi, T.; Lee, P.Y.; Wang, R.F.; Podos, S.M. Effects of  $Al^{3+}$  and  $Be^{2+}$  ions combined with NaF on ciliary process adenylyl cyclase activity and aqueous humor dynamics in the rabbit eye. *Investig. Ophthalmol. Vis. Sci.* **1993**, *34*, 606–612.
27. Dunn, T.A.; Storm, D.R.; Feller, M.B. Calcium-dependent increases in protein kinase-A activity in mouse retinal ganglion cells are mediated by multiple adenylate cyclases. *PLoS ONE* **2009**, *4*, e7877. [[CrossRef](#)] [[PubMed](#)]
28. Schmidt, K.-G.; Geyer, O.; Mittag, T.W. Adenylyl and guanylyl cyclase activity in the choroid. *Exp. Eye Res.* **2004**, *78*, 901–907. [[CrossRef](#)] [[PubMed](#)]
29. Tao, Y.; Pan, M.; Liu, S.; Fang, F.; Lu, R.; Lu, C.; Zheng, M.; An, J.; Xu, H.; Zhao, F.; et al. cAMP Level Modulates Scleral Collagen Remodeling, a Critical Step in the Development of Myopia. *PLoS ONE* **2013**, *8*, e71441. [[CrossRef](#)]
30. Berczeli, O.; Szarka, D.; Elekes, G.; Vizvári, E.; Szalay, L.; Almássy, J.; Tálosi, L.; Ding, C.; Tóth-Molnár, E. The regulatory role of vasoactive intestinal peptide in lacrimal gland ductal fluid secretion: A new piece of the puzzle in tear production. *Mol. Vis.* **2020**, *26*, 780–788.
31. Pavan, B.; Frigato, E.; Pozzati, S.; Prasad, P.D.; Bertolucci, C.; Biondi, C. Circadian clocks regulate adenylyl cyclase activity rhythms in human RPE cells. *Biochem. Biophys. Res. Commun.* **2006**, *350*, 169–173. [[CrossRef](#)] [[PubMed](#)]
32. Sun, X.C.; Zhai, C.-B.; Cui, M.; Chen, Y.; Levin, L.R.; Buck, J.; Bonanno, J.A.  $HCO_3^-$ -dependent soluble adenylyl cyclase activates cystic fibrosis transmembrane conductance regulator in corneal endothelium. *Am. J. Physiol. Cell Physiol.* **2003**, *284*, C1114–C1122. [[CrossRef](#)] [[PubMed](#)]
33. Kuang, K.Y.; Xu, M.; Koniarek, J.P.; Fischbarg, J. Effects of ambient bicarbonate, phosphate and carbonic anhydrase inhibitors on fluid transport across rabbit corneal endothelium. *Exp. Eye Res.* **1990**, *50*, 487–493. [[CrossRef](#)] [[PubMed](#)]
34. Sun, X.C.; Bonanno, J.A. Expression, localization, and functional evaluation of CFTR in bovine corneal endothelial cells. *Am. J. Physiol. Cell Physiol.* **2002**, *282*, C673–C683. [[CrossRef](#)] [[PubMed](#)]
35. Steegborn, C.; Litvin, T.N.; Levin, L.R.; Buck, J.; Wu, H. Bicarbonate activation of adenylyl cyclase via promotion of catalytic active site closure and metal recruitment. *Nat. Struct. Mol. Biol.* **2005**, *12*, 32–37. [[CrossRef](#)] [[PubMed](#)]
36. Tresguerres, M.; Buck, J.; Levin, L.R. Physiological carbon dioxide, bicarbonate, and pH sensing. *Pflug. Arch.* **2010**, *460*, 953–964. [[CrossRef](#)]
37. Edelhauser, H.F. The balance between corneal transparency and edema: The Proctor Lecture. *Investig. Ophthalmol. Vis. Sci.* **2006**, *47*, 1754–1767. [[CrossRef](#)] [[PubMed](#)]
38. Riley, M.V.; Winkler, B.S.; Starnes, C.A.; Peters, M.I. Adenosine promotes regulation of corneal hydration through cyclic adenosine monophosphate. *Investig. Ophthalmol. Vis. Sci.* **1996**, *37*, 1–10.
39. Li, S.; Allen, K.T.; Bonanno, J.A. Soluble adenylyl cyclase mediates bicarbonate-dependent corneal endothelial cell protection. *Am. J. Physiol.-Cell Physiol.* **2011**, *300*, C368–C374. [[CrossRef](#)]
40. Grueb, M.; Bartz-Schmidt, K.U.; Rohrbach, J.M. Adrenergic regulation of cAMP/protein kinase A pathway in corneal epithelium and endothelium. *Ophthalmic Res.* **2008**, *40*, 322–328. [[CrossRef](#)]
41. Lass, J.H.; Spurney, R.V.; Dutt, R.M.; Andersson, H.; Kochar, H.; Rodman, H.M.; Stern, R.C.; Doershuk, C.F. A morphologic and fluorophotometric analysis of the corneal endothelium in type I diabetes mellitus and cystic fibrosis. *Am. J. Ophthalmol.* **1985**, *100*, 783–788. [[CrossRef](#)]
42. Michael, R.; Bron, A.J. The ageing lens and cataract: A model of normal and pathological ageing. *Philos. Trans. R. Soc. B Biol. Sci.* **2011**, *366*, 1278–1292. [[CrossRef](#)] [[PubMed](#)]
43. Hur, K.C.; Louis, C.F. Regional distribution of the enzymes and substrates mediating the action of cAMP in the mammalian lens. *Biochim. Biophys. Acta* **1989**, *1010*, 56–63. [[CrossRef](#)] [[PubMed](#)]
44. Bizec, J.C.; Klethi, J.; Mandel, P. Modulation of adenylate cyclase activity in bovine lens epithelial cells. *Ophthalmic Res.* **1989**, *21*, 167–174. [[CrossRef](#)]
45. Bizec, J.C.; Klethi, J.; Mandel, P. Calcium-dependent regulation of adenylate cyclase and phosphodiesterase activities in bovine lens: Involvement of lens calmodulin. *Exp. Eye Res.* **1985**, *41*, 239–247. [[CrossRef](#)]
46. Shahidullah, M.; Mandal, A.; Delamere, N.A. A Role for Calcium-Activated Adenylate Cyclase and Protein Kinase A in the Lens Src Family Kinase and Na,K-ATPase Response to Hyposmotic Stress. *Investig. Ophthalmol. Vis. Sci.* **2017**, *58*, 4447–4456. [[CrossRef](#)]
47. Lee, Y.S.; Marmorstein, A.D. Control of Outflow Resistance by Soluble Adenylyl Cyclase. *J. Ocul. Pharmacol. Ther.* **2014**, *30*, 138–142. [[CrossRef](#)]
48. Goh, Y.; Hotehama, Y.; Mishima, H.K. Characterization of ciliary muscle relaxation induced by various agents in cats. *Investig. Ophthalmol. Vis. Sci.* **1995**, *36*, 1188–1192.

49. Nii, H.; Ikeda, H.; Okada, K.; Yoshitomi, T.; Gregory, D.S. Circadian change of adenylate cyclase activity in rabbit ciliary processes. *Curr. Eye Res.* **2001**, *23*, 248–255. [[CrossRef](#)]
50. Koçak, I.; Orgül, S.; Saruhan, A.; Haefliger, I.; Hendrickson, P.; Flammer, J. Measurement of intraocular pressure with a modern noncontact tonometer. *Ophthalmologica* **1998**, *212*, 81–87. [[CrossRef](#)]
51. Mittag, T.W.; Tormay, A.; Podos, S.M. Vasoactive intestinal peptide and intraocular pressure: Adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes. *J. Pharmacol. Exp. Ther.* **1987**, *241*, 230–235. [[PubMed](#)]
52. Wu, R.; Ma, N.; Hu, Q. Effect of cAMP on short-circuit current in isolated human ciliary body. *Chin. Med. J.* **2013**, *126*, 2694–2698. [[PubMed](#)]
53. Crook, R.B.; Polansky, J.R. Stimulation of Na<sup>+</sup>,K<sup>+</sup>,Cl<sup>-</sup> cotransport by forskolin-activated adenylate cyclase in fetal human nonpigmented epithelial cells. *Investig. Ophthalmol. Vis. Sci.* **1994**, *35*, 3374–3383.
54. Caprioli, J.; Sears, M.; Bausher, L.; Gregory, D.; Mead, A. Forskolin lowers intraocular pressure by reducing aqueous inflow. *Investig. Ophthalmol. Vis. Sci.* **1984**, *25*, 268–277.
55. Araie, M. Time change of rabbit aqueous flow under influence of adrenergic drugs. *Exp. Eye Res.* **1985**, *41*, 391–403. [[CrossRef](#)]
56. Matsumoto, S.; Yamashita, T.; Araie, M.; Kametani, S.; Hosokawa, T.; Takase, M. The ocular penetration of topical forskolin and its effects on intraocular pressure, aqueous flow rate and cyclic AMP level in the rabbit eye. *Jpn. J. Ophthalmol.* **1990**, *34*, 428–435. [[PubMed](#)]
57. Coakes, R.L.; Siah, P.B. Effects of adrenergic drugs on aqueous humour dynamics in the normal human eye. I. Salbutamol. *Br. J. Ophthalmol.* **1984**, *68*, 393–397. [[CrossRef](#)] [[PubMed](#)]
58. Robinson, J.; Okoro, E.; Ezuedu, C.; Bush, L.; Opere, C.A.; Ohia, S.E.; Njie-Mbye, Y.F. Effects of Hydrogen Sulfide-Releasing Compounds on Aqueous Humor Outflow Facility in Porcine Ocular Anterior Segments, Ex Vivo. *J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther.* **2017**, *33*, 91–97. [[CrossRef](#)] [[PubMed](#)]
59. Zhang, X.; Wang, N.; Schroeder, A.; Erickson, K.A. Expression of adenylate cyclase subtypes II and IV in the human outflow pathway. *Investig. Ophthalmol. Vis. Sci.* **2000**, *41*, 998–1005.
60. Busch, M.J.; Kobayashi, K.; Hoyng, P.F.; Mittag, T.W. Adenylate cyclase in human and bovine trabecular meshwork. *Investig. Ophthalmol. Vis. Sci.* **1993**, *34*, 3028–3034.
61. Dijkstra, B.G.; Schneemann, A.; Hoyng, P.F. Flow after prostaglandin E1 is mediated by receptor-coupled adenylate cyclase in human anterior segments. *Investig. Ophthalmol. Vis. Sci.* **1999**, *40*, 2622–2626.
62. Bhattacharjee, P.; Jacobs, N.; Coca-Prados, M.; Paterson, C. Identification of prostanoid receptors in rabbit non-pigmented ciliary epithelial cells. *Exp. Eye Res.* **1996**, *62*, 491–498. [[CrossRef](#)] [[PubMed](#)]
63. Shim, M.S.; Kim, K.-Y.; Ju, W.-K. Role of cyclic AMP in the eye with glaucoma. *BMB Rep.* **2017**, *50*, 60–70. [[CrossRef](#)] [[PubMed](#)]
64. Shahidullah, M.; Mandal, A.; Wei, G.; Levin, L.R.; Buck, J.; Delamere, N.A. Nonpigmented ciliary epithelial cells respond to acetazolamide by a soluble adenylate cyclase mechanism. *Investig. Ophthalmol. Vis. Sci.* **2014**, *55*, 187–197. [[CrossRef](#)] [[PubMed](#)]
65. Wiggins, S.V.; Schreiner, R.; Ferreira, J.; Marmorstein, A.D.; Levin, L.R.; Buck, J. Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylate Cyclase. *J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther.* **2023**, *39*, 317–323. [[CrossRef](#)] [[PubMed](#)]
66. Agarwal, R.; Agarwal, P. Newer targets for modulation of intraocular pressure: Focus on adenosine receptor signaling pathways. *Expert Opin. Ther. Targets* **2014**, *18*, 527–539. [[CrossRef](#)]
67. Wang, J.; Zhang, N.; Beuve, A.; Townes-Anderson, E. Mislocalized opsin and cAMP signaling: A mechanism for sprouting by rod cells in retinal degeneration. *Investig. Ophthalmol. Vis. Sci.* **2012**, *53*, 6355–6369. [[CrossRef](#)]
68. Nicol, X.; Bennis, M.; Ishikawa, Y.; Chan, G.C.-K.; Repérant, J.; Storm, D.R.; Gaspar, P. Role of the calcium modulated cyclases in the development of the retinal projections. *Eur. J. Neurosci.* **2006**, *24*, 3401–3414. [[CrossRef](#)]
69. Ohia, S.E.; Opere, C.; Tang, L.; al-Zadjali, K. Role of cyclic AMP in prostaglandin mediated responses in the neural retina. *J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther.* **1995**, *11*, 73–81. [[CrossRef](#)]
70. Tremblay, F.; Abdel-Majid, R.; Neumann, P.E. Electroretinographic oscillatory potentials are reduced in adenylate cyclase type I deficient mice. *Vis. Res.* **2002**, *42*, 1715–1725. [[CrossRef](#)]
71. Zhang, Z.; Liu, Y.; Luan, Y.; Zhu, K.; Hu, B.; Ma, B.; Chen, L.; Liu, X.; Lu, H.; Chen, X.; et al. Activation of Type 4 Metabotropic Glutamate Receptor Regulates Proliferation and Neuronal Differentiation in a Cultured Rat Retinal Progenitor Cell Through the Suppression of the cAMP/PDEN/AKT Pathway. *Front. Mol. Neurosci.* **2020**, *13*, 141. [[CrossRef](#)] [[PubMed](#)]
72. Dong, C.-J.; Guo, Y.; Ye, Y.; Hare, W.A. Presynaptic inhibition by  $\alpha 2$  receptor/adenylate cyclase/PDE4 complex at retinal rod bipolar synapse. *J. Neurosci. Off. J. Soc. Neurosci.* **2014**, *34*, 9432–9440. [[CrossRef](#)] [[PubMed](#)]
73. Li, H.; Chuang, A.Z.; O'Brien, J. Regulation of photoreceptor gap junction phosphorylation by adenosine in zebrafish retina. *Vis. Neurosci.* **2014**, *31*, 237–243. [[CrossRef](#)]
74. Hattar, S.; Liao, H.W.; Takao, M.; Berson, D.M.; Yau, K.W. Melanopsin-containing retinal ganglion cells: Architecture, projections, and intrinsic photosensitivity. *Science* **2002**, *295*, 1065–1070. [[CrossRef](#)] [[PubMed](#)]
75. Varella, M.H.; Correa, D.F.; Campos, C.B.; Chiarini, L.B.; Linden, R. Protein kinases selectively modulate apoptosis in the developing retina in vitro. *Neurochem. Int.* **1997**, *31*, 217–227. [[CrossRef](#)] [[PubMed](#)]
76. Lakk, M.; Denes, V.; Gabriel, R. Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Signal via Phospholipase C Pathway to Block Apoptosis in Newborn Rat Retina. *Neurochem. Res.* **2015**, *40*, 1402–1409. [[CrossRef](#)]

77. Njaine, B.; Martins, R.A.P.; Santiago, M.F.; Linden, R.; Silveira, M.S. Pituitary adenylyl cyclase-activating polypeptide controls the proliferation of retinal progenitor cells through downregulation of cyclin D1. *Eur. J. Neurosci.* **2010**, *32*, 311–321. [[CrossRef](#)] [[PubMed](#)]
78. Silveira, M.S.; Costa, M.R.; Bozza, M.; Linden, R. Pituitary adenylyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. *J. Biol. Chem.* **2002**, *277*, 16075–16080. [[CrossRef](#)]
79. Santos, R.C.; Araujo, E.G. Cyclic AMP increases the survival of ganglion cells in mixed retinal cell cultures in the absence of exogenous neurotrophic molecules, an effect that involves cholinergic activity. *Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Medicas E Biol.* **2001**, *34*, 1585–1593. [[CrossRef](#)]
80. Gregory, C.Y.; Abrams, T.A.; Hall, M.O. cAMP production via the adenylyl cyclase pathway is reduced in RCS rat RPE. *Investig. Ophthalmol. Vis. Sci.* **1992**, *33*, 3121–3124.
81. Cameron, E.G.; Nahmou, M.; Toth, A.B.; Heo, L.; Tanasa, B.; Dalal, R.; Yan, W.; Nallagatla, P.; Xia, X.; Hay, S.; et al. A molecular switch for neuroprotective astrocyte reactivity. *Nature* **2024**, *626*, 574–582. [[CrossRef](#)] [[PubMed](#)]
82. da Encarnação, T.G.; Portugal, C.C.; Nogueira, C.E.; Santiago, F.N.; Socodato, R.; Paes-de-Carvalho, R. Dopamine Promotes Ascorbate Release from Retinal Neurons: Role of D1 Receptors and the Exchange Protein Directly Activated by cAMP type 2 (EPAC2). *Mol. Neurobiol.* **2018**, *55*, 7858–7871. [[CrossRef](#)] [[PubMed](#)]
83. Paradis, H.; Werdyani, S.; Zhai, G.; Gendron, R.L.; Tabrizchi, R.; McGovern, M.; Jumper, J.M.; Brinton, D.; Good, W.V. Genetic Variants of the Beta-Adrenergic Receptor Pathways as Both Risk and Protective Factors for Retinopathy of Prematurity. *Am. J. Ophthalmol.* **2024**, *263*, 179–187. [[CrossRef](#)] [[PubMed](#)]
84. Chen, Y.; Palczewska, G.; Mustafi, D.; Golczak, M.; Dong, Z.; Sawada, O.; Maeda, T.; Maeda, A.; Palczewski, K. Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. *J. Clin. Investig.* **2013**, *123*, 5119–5134. [[CrossRef](#)]
85. Hurley, J.B. Retina Metabolism and Metabolism in the Pigmented Epithelium: A Busy Intersection. *Annu. Rev. Vis. Sci.* **2021**, *7*, 665–692. [[CrossRef](#)] [[PubMed](#)]
86. Huang, C.C.Y.; Shi, L.; Lin, C.-H.; Kim, A.J.; Ko, M.L.; Ko, G.Y.-P. A new role for AMP-activated protein kinase in the circadian regulation of L-type voltage-gated calcium channels in late-stage embryonic retinal photoreceptors. *J. Neurochem.* **2015**, *135*, 727–741. [[CrossRef](#)] [[PubMed](#)]
87. Chaurasia, S.S.; Haque, R.; Pozdeyev, N.; Jackson, C.R.; Iuvone, P.M. Temporal coupling of cyclic AMP and Ca/calmodulin-stimulated adenylyl cyclase to the circadian clock in chick retinal photoreceptor cells. *J. Neurochem.* **2006**, *99*, 1142–1150. [[CrossRef](#)]
88. Ivanova, T.N.; Iuvone, P.M. Circadian rhythm and photic control of cAMP level in chick retinal cell cultures: A mechanism for coupling the circadian oscillator to the melatonin-synthesizing enzyme, arylalkylamine N-acetyltransferase, in photoreceptor cells. *Brain Res.* **2003**, *991*, 96–103. [[CrossRef](#)]
89. Hwang, C.K.; Chaurasia, S.S.; Jackson, C.R.; Chan, G.C.-K.; Storm, D.R.; Iuvone, P.M. Circadian rhythm of contrast sensitivity is regulated by a dopamine-neuronal PAS-domain protein 2-adenylyl cyclase 1 signaling pathway in retinal ganglion cells. *J. Neurosci. Off. J. Soc. Neurosci.* **2013**, *33*, 14989–14997. [[CrossRef](#)]
90. de Andrade, M.J.O. Circadian Sensation and Visual Perception. In *Circadian Rhythm—New Insights into Physiological and Pathological Implications*; IntechOpen: London, UK, 2021; ISBN 978-1-80355-370-2. Available online: <https://www.intechopen.com/chapters/79581> (accessed on 24 April 2024).
91. Jackson, C.R.; Chaurasia, S.S.; Hwang, C.K.; Iuvone, P.M. Dopamine D<sub>4</sub> receptor activation controls circadian timing of the adenylyl cyclase 1/cyclic AMP signaling system in mouse retina. *Eur. J. Neurosci.* **2011**, *34*, 57–64. [[CrossRef](#)]
92. Fukuhara, C.; Liu, C.; Ivanova, T.N.; Chan, G.C.-K.; Storm, D.R.; Iuvone, P.M.; Tosini, G. Gating of the cAMP signaling cascade and melatonin synthesis by the circadian clock in mammalian retina. *J. Neurosci. Off. J. Soc. Neurosci.* **2004**, *24*, 1803–1811. [[CrossRef](#)] [[PubMed](#)]
93. Tosini, G.; Baba, K.; Hwang, C.K.; Iuvone, P.M. Melatonin: An underappreciated player in retinal physiology and pathophysiology. *Exp. Eye Res.* **2012**, *103*, 82–89. [[CrossRef](#)] [[PubMed](#)]
94. The epidemiology of dry eye disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). *Ocul. Surf.* **2007**, *5*, 93–107. [[CrossRef](#)] [[PubMed](#)]
95. Hodges, R.R.; Zoukhri, D.; Sergheraert, C.; Zieske, J.D.; Dartt, D.A. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components. *Investig. Ophthalmol. Vis. Sci.* **1997**, *38*, 610–619.
96. Said, S.I.; Mutt, V. A peptide fraction from lung tissue with prolonged peripheral vasodilator activity. *Scand. J. Clin. Lab. Investig. Suppl.* **1969**, *107*, 51–56.
97. Gilbard, J.P.; Dartt, D.A.; Rood, R.P.; Rossi, S.R.; Gray, K.L.; Donowitz, M. Increased tear secretion in pancreatic cholera: A newly recognized symptom in an experiment of nature. *Am. J. Med.* **1988**, *85*, 552–554. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.